Price T Rowe Associates Inc Adverum Biotechnologies, Inc. Transaction History

Price T Rowe Associates Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$1.74 - $2.4 $94,125 - $129,828	-54,095 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$3.36 - $10.56 $1.76 Million - $5.54 Million	-524,831 Reduced 90.66%	54,095 $189,000
Q1 2021 May 17, 2021	SELL	$9.26 - $14.36 $9.99 Million - $15.5 Million	-1,078,507 Reduced 65.07%	578,926 $5.71 Million
Q4 2020 Feb 16, 2021	BUY	$9.84 - $14.26 $16.3 Million - $23.6 Million	1,657,433 New	1,657,433 $18 Million

3.6M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $681M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

Stay updated on Price T Rowe Associates Inc with notifications on news.